Zacks Investment Management Innoviva, Inc. Transaction History

Zacks Investment Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$11.06 - $12.87 $913,456 - $1.06 Million	-82,591 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.33 - $12.48 $478,955 - $640,660	51,335 Added 164.24%	82,591 $1.02 Million
Q3 2020 Nov 16, 2020	SELL	$10.33 - $14.49 $49,129 - $68,914	-4,756 Reduced 13.21%	31,256 $327,000
Q2 2020 Aug 14, 2020	BUY	$11.49 - $15.26 $140,867 - $187,087	12,260 Added 51.62%	36,012 $503,000
Q1 2020 May 15, 2020	BUY	$8.11 - $15.23 $192,628 - $361,742	23,752 New	23,752 $279,000
Q3 2019 Nov 14, 2019	SELL	$10.05 - $14.55 $326,142 - $472,176	-32,452 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$13.1 - $14.95 $425,121 - $485,157	32,452 New	32,452 $473,000
Q4 2017 Feb 14, 2018	SELL	$11.73 - $14.75 $125,909 - $158,326	-10,734 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.06 - $14.12 $129,452 - $151,564	10,734	10,734 $152,000

240

77M

53.9K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.26B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.